Latest in Cardiology from ACC.org

• New Global Burden of CVD Report Shows Wide Variation Among Countries
  Cardiovascular disease remains the leading cause of disease burden, causing one in three deaths worldwide, according to the latest Global Burden of Disease study report published Sept. 24 in JACC and presented during a special side event as part of the 80th Session of the United Nations General Assembly in New York.
• OASIS 4: Significant Weight Loss With Oral Semaglutide Comparable With High-Dose, SC Versions
  Oral semaglutide 25 mg once daily was associated with significant weight loss vs. placebo, comparable with that seen with the 50 mg oral dose and with the subcutaneous (SC) injectable version of the drug, according to new results from the phase 3 OASIS 4 trial, published Sept. 17 in NEJM.
• Metoprolol Versus Aficamten in Patients With Left Ventricular Outflow Tract Obstruction on Exercise Capacity in HCM
  The MAPLE-HCM trial showed that, among patients with symptomatic obstructive HCM, aficamten monotherapy was superior to metoprolol monotherapy in improving peak oxygen uptake and hemodynamics, and decreasing symptoms.
• A Study of Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy
  Among patients with nonobstructive HCM in the ODYSSEY-HCM trial, mavacamten failed to significantly improve peak oxygen uptake or improve health status compared with placebo.
• ATTAIN-1: Oral Orforglipron Significantly Reduces Weight, Cardiometabolic Risk
  Orforglipron, a small-molecule, nonpeptide oral GLP-1 receptor agonist, at multiple doses produced significant weight loss and improved cardiometabolic risk factors compared with placebo, according to the phase 3 ATTAIN-1 trial, presented at the European Association for the Study of Diabetes General Assembly 2025 and simultaneously published Sept. 16 in NEJM.